PA
VIRX

Perceptive Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Perceptive Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,905
Closed -$2.86M – 167
2014
Q3 		$2.86M Buy
+1,905
New +$2.76M 0.29% 58

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors's VIRX Position: Q4 2015 in Review

Perceptive Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2015, closing a stake of 3,333 shares — an estimated $567K sold.

Perceptive Advisors first reported a position in VIRX in Q2 2013 and held it in 5 quarters. The position peaked at $2.11M in Q2 2015. 55 funds tracked by Wall St. Rank hold VIRX as of Q4 2015.

  • Perceptive Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Perceptive Advisors sold 3,333 Viracta Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $567K.
  • Perceptive Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
  • Perceptive Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $2.11M in Q2 2015.
  • 55 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.